A new study from researchers in 2026 reports that tumor progression can disrupt ovarian function even when tumors are not reproductive in origin. Published in Experimental and Molecular Medicine, the work pinpoints an inflammatory signaling route linking tumor-driven immune cues to ovarian dysfunction.
Using mechanistic experiments in disease models, the team focused on the CXCL10–IL18R1 axis, a pathway known to orchestrate communication between immune cells and target tissues. Their data suggest that as non-reproductive tumors advance, they increase the production or signaling of CXCL10, a chemokine that helps shape immune cell recruitment and activation.
The key finding is that ovarian impairment is not merely a passive consequence of illness. Instead, it involves receptor-dependent response to inflammatory signals. IL18R1, the receptor for interleukin-18, emerged as a crucial mediator, with ovarian cells and/or associated stromal and immune compartments showing pathway engagement during tumor progression.
The study reports that activation of CXCL10-linked signaling correlates with heightened IL18R1 activity, leading to downstream inflammatory cascades that negatively affect ovarian physiology. These cascades are associated with altered tissue homeostasis, impaired functional markers, and evidence consistent with reduced reproductive capacity.
Importantly, the authors emphasize the axis as a potential driver rather than a bystander. When components of the CXCL10–IL18R1 pathway were experimentally perturbed, the severity of ovarian dysfunction diminished, strengthening the causal link.
From a translational perspective, the results raise the possibility that targeting chemokine signaling or IL18R1-mediated pathways could help protect reproductive function in patients whose tumors are unrelated to the reproductive tract. Such interventions could complement existing cancer therapies by preserving long-term fertility outcomes.
The broader implication is that inflammation generated by tumors can “reach” distant organs through defined immune axes. By mapping one such route—CXCL10 to IL18R1—the research provides a more actionable framework for preventing collateral reproductive damage.
Overall, the study reframes tumor progression as an immunologically wired process with measurable effects on ovarian performance, highlighting the CXCL10–IL18R1 axis as a promising target for future fertility-sparing strategies in oncology.
Subject of Research: Non-reproductive tumor progression and ovarian function impairment via immune signaling.
Article Title: Non-reproductive tumor progression impairs ovarian function through CXCL10–IL18R1 axis.
Article References: Xie, SY., Zhang, SP., Li, CR. et al. Exp Mol Med (2026). https://doi.org/10.1038/s12276-026-01790-4
Image Credits: AI Generated
DOI: 10.1038/s12276-026-01790-4
Keywords:
